Fluoroquinolones and the Risk for Methicillin-resistant Staphylococcus aureus in Hospitalized Patients
2003

Fluoroquinolones and MRSA Risk in Hospitalized Patients

Sample size: 343 publication 10 minutes Evidence: high

Author Information

Author(s): Weber Stephen G., Gold Howard S., Hooper David C., Karchmer A.W., Carmeli Yehuda

Primary Institution: Beth Israel Deaconess Medical Center and Harvard Medical School

Hypothesis

Is fluoroquinolone exposure a risk factor for the isolation of Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA)?

Conclusion

Exposure to fluoroquinolones, specifically levofloxacin and ciprofloxacin, is a significant risk factor for the isolation of MRSA in hospitalized patients.

Supporting Evidence

  • 67.6% of MRSA patients were exposed to fluoroquinolones compared to 22.7% of MSSA patients.
  • Exposure to levofloxacin was associated with an OR of 5.4 for MRSA isolation.
  • Exposure to ciprofloxacin was associated with an OR of 2.2 for MRSA isolation.
  • 97% of MRSA isolates were resistant to fluoroquinolones.
  • Univariate analysis showed significant associations between fluoroquinolone exposure and MRSA.

Takeaway

Taking certain antibiotics called fluoroquinolones can make you more likely to get a type of bacteria called MRSA, which is hard to treat.

Methodology

The study used a case-case-control design with two groups of patients who had MRSA and MSSA, comparing them to a control group of patients without these infections.

Potential Biases

Potential bias from using patients colonized or infected with sensitive strains as controls in previous studies.

Limitations

The study may have biases due to the selection of control patients and the retrospective nature of data collection.

Participant Demographics

Mean age of MRSA cases was 66.2 years, MSSA cases was 63.3 years, and controls was 57.6 years; 56.8% of MRSA patients and 55.8% of MSSA patients were men.

Statistical Information

P-Value

p < 0.0001 for levofloxacin, p = 0.005 for ciprofloxacin

Confidence Interval

OR 3.4 (1.94 to 5.90) for levofloxacin, OR 2.5 (1.32 to 4.67) for ciprofloxacin

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3201/eid0911.030284

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication